Viracta Therapeutics, Inc. (VIRX) Misses Q2 EPS by 3c

Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Lyft to acquire Serveo's bikeshare business in Spain
• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook